Clinical Trial

First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults

Name: First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults — clinical trial record (NCT07646353)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.

Trial Details

NCT Number	NCT07646353
Lead Sponsor	GlaxoSmithKline
Conditions	Malaria, Falciparum
Enrollment	40 participants
Start Date	2026-06-12
Primary Completion	2028-04-19 (estimated)
Study Completion	2028-04-19 (estimated)
Updated on ClinicalTrials.gov	2026-06-12